The UK Hormones in Dosage (excluding contraceptives and antibiotics) market is forecasted to decrease steadily from $2.7972 billion in 2024 to $1.9604 billion in 2028. Compared to 2023, which recorded an actual market value higher than 2024's forecast, the market demonstrates a negative growth trajectory. Specifically, year-on-year declines are noted with a substantial contraction annually. Over this five-year period, the compound annual growth rate (CAGR) indicates a consistent downward trend in this market segment.

Future trends to watch for:

Changing healthcare needs and regulatory impacts could further influence market dynamics.
Potential innovations in hormonal therapies might stabilize demand or spur niche market growth.
Increased focus on personalized medicine could alter product offerings and consumer preference.